表紙:多発性硬化症:疫学的予測
市場調査レポート
商品コード
601992

多発性硬化症:疫学的予測

Multiple Sclerosis -Epidemiology Forecast to 2028

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 50 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.84円
多発性硬化症:疫学的予測
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 50 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の多発性硬化症の疫学的予測について分析し、疾患の概要や現在の治療手法/アルゴリズム、世界全体および主要国 (米国・欧州諸国・日本) での有病者数の動向見通し (通算12年間分)、男女別・年齢別・サブタイプ別等の詳細動向、今後の市場機会・医薬品開発の見通しなどについて調査しております。

第1章 イントロダクション

第2章 多発性硬化症の疫学:市場概略

  • 多発性硬化症の患者人口 (最新値・予測値)

第3章 疾患の背景事情と概要

  • イントロダクション
  • リスク要因
  • 病因
  • 症状
  • 病態形成
  • EDSS (神経症状評価尺度)

第4章 疫学と患者人口

  • 分析のポイント
  • 患者人口と予測パラメーター
  • 多発性硬化症の有病者数:主要7ヶ国 (7MM) の場合
  • 多発性硬化症の有病者数:主要7ヶ国 (7MM) の場合、地域別
  • 多発性硬化症の有病者数:主要7ヶ国 (7MM) の場合、分布構造 (最新値)
  • 多発性硬化症の有病者数:主要7ヶ国 (7MM) の場合、分布構造 (予測値)

第5章 多発性硬化症の疫学

第6章 米国

  • 前提条件と合理的理由
  • 多発性硬化症の有病者数
  • 多発性硬化症の有病者数:男女別
  • 多発性硬化症の有病者数:サブタイプ別
  • 多発性硬化症の有病者数:年齢層別
  • 多発性硬化症の有病者数:EDSSスコア別

第7章 ドイツ

第8章 フランス

第9章 イタリア

第10章 スペイン

第11章 英国

第12章 日本

第13章 アンメットニーズ

第14章 付録

第15章 分析手法

  • 情報源

第16章 コンサルティングサービス

第17章 免責事項

第18章 DelveInsightについて

図表

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Multiple Sclerosis in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Multiple Sclerosis in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Multiple Sclerosis in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Multiple Sclerosis in United States (2016-2028)*
  • Table 5: Sex- Specific Cases of the Multiple Sclerosis in United States (2016-2028)*
  • Table 6: Diagnosed Cases of the Multiple Sclerosis in United States (2016-2028)
  • Table 7: Prevalent/Incident Cases of the Multiple Sclerosis in Germany (2016-2028)
  • Table 8: Sub-Type Specific cases of the Multiple Sclerosis in Germany (2016-2028) *
  • Table 9: Sex- Specific Cases of the Multiple Sclerosis in Germany (2016-2028) *
  • Table 10: Diagnosed Cases of the Multiple Sclerosis in Germany (2016-2028)
  • Table 11: Prevalent/Incident Cases of the Multiple Sclerosis in France (2016-2028)
  • Table 12: Sub-Type Specific cases of the Multiple Sclerosis in France (2016-2028) *
  • Table 13: Sex- Specific Cases of the Multiple Sclerosis in France (2016-2028) *
  • Table 14: Diagnosed Cases of the Multiple Sclerosis in France (2016-2028)
  • Table 15: Prevalent/Incident Cases of the Multiple Sclerosis in Italy (2016-2028)
  • Table 16: Sub-Type Specific cases of the Multiple Sclerosis in Italy (2016-2028) *
  • Table 17: Sex- Specific Cases of the Multiple Sclerosis in Italy (2016-2028) *
  • Table 18: Diagnosed Cases of the Multiple Sclerosis in Italy (2016-2028)
  • Table 19: Prevalent/Incident Cases of the Multiple Sclerosis in Spain (2016-2028)
  • Table 20: Sub-Type Specific cases of the Multiple Sclerosis in Spain (2016-2028) *
  • Table 21: Sex- Specific Cases of the Multiple Sclerosis in Spain (2016-2028) *
  • Table 22: Diagnosed Cases of the Multiple Sclerosis in Spain (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Multiple Sclerosis in UK (2016-2028)
  • Table 24: Sub-Type Specific cases of the Multiple Sclerosis in UK (2016-2028) *
  • Table 25: Sex- Specific Cases of the Multiple Sclerosis in UK (2016-2028) *
  • Table 26: Diagnosed Cases of the Multiple Sclerosis in UK (2016-2028)
  • Table 27: Prevalent/Incident Cases of the Multiple Sclerosis in Japan (2016-2028)
  • Table 28: Sub-Type Specific cases of the Multiple Sclerosis in Japan (2016-2028) *
  • Table 29: Sex- Specific Cases of the Multiple Sclerosis in Japan (2016-2028) *
  • Table 30: Diagnosed Cases of the Multiple Sclerosis in Japan (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Multiple Sclerosis in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Multiple Sclerosis in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Multiple Sclerosis in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Multiple Sclerosis in United States (2016-2028)*
  • Figure 5: Sex- Specific Cases of the Multiple Sclerosis in United States (2016-2028)*
  • Figure 6: Diagnosed Cases of the Multiple Sclerosis in United States (2016-2028)
  • Figure 7: Prevalent/Incident Cases of the Multiple Sclerosis in Germany (2016-2028)
  • Figure 8: Sub-Type Specific cases of the Multiple Sclerosis in Germany (2016-2028) *
  • Figure 9: Sex- Specific Cases of the Multiple Sclerosis in Germany (2016-2028) *
  • Figure 10: Diagnosed Cases of the Multiple Sclerosis in Germany (2016-2028)
  • Figure 11: Prevalent/Incident Cases of the Multiple Sclerosis in France (2016-2028)
  • Figure 12: Sub-Type Specific cases of the Multiple Sclerosis in France (2016-2028) *
  • Figure 13: Sex- Specific Cases of the Multiple Sclerosis in France (2016-2028) *
  • Figure 14: Diagnosed Cases of the Multiple Sclerosis in France (2016-2028)
  • Figure 15: Prevalent/Incident Cases of the Multiple Sclerosis in Italy (2016-2028)
  • Figure 16: Sub-Type Specific cases of the Multiple Sclerosis in Italy (2016-2028) *
  • Figure 17: Sex- Specific Cases of the Multiple Sclerosis in Italy (2016-2028) *
  • Figure 18: Diagnosed Cases of the Multiple Sclerosis in Italy (2016-2028)
  • Figure 19: Prevalent/Incident Cases of the Multiple Sclerosis in Spain (2016-2028)
  • Figure 20: Sub-Type Specific cases of the Multiple Sclerosis in Spain (2016-2028) *
  • Figure 21: Sex- Specific Cases of the Multiple Sclerosis in Spain (2016-2028) *
  • Figure 22: Diagnosed Cases of the Multiple Sclerosis in Spain (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Multiple Sclerosis in UK (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Multiple Sclerosis in UK (2016-2028) *
  • Figure 25: Sex- Specific Cases of the Multiple Sclerosis in UK (2016-2028) *
  • Figure 26: Diagnosed Cases of the Multiple Sclerosis in UK (2016-2028)
  • Figure 27: Prevalent/Incident Cases of the Multiple Sclerosis in Japan (2016-2028)
  • Figure 28: Sub-Type Specific cases of the Multiple Sclerosis in Japan (2016-2028) *
  • Figure 29: Sex- Specific Cases of the Multiple Sclerosis in Japan (2016-2028) *
  • Figure 30: Diagnosed Cases of the Multiple Sclerosis in Japan (2016-2028)
目次
Product Code: DIEI0322

DelveInsight's "Multiple Sclerosis - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Multiple Sclerosis epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Multiple Sclerosis Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Multiple Sclerosis in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Multiple Sclerosis outlook. It also includes the explanation of changing trends of epidemiology outlining the Multiple Sclerosis scenario.

Multiple Sclerosis Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Multiple Sclerosis thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

  • The report covers detailed overview of Multiple Sclerosis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Multiple Sclerosis Report assesses the disease risk and burden and highlights the unmet needs
  • It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Total Cases in Multiple Sclerosis

Key assessments

  • Patient Segmentation in Multiple Sclerosis
  • Multiple Sclerosis Risk & Burden
  • Factors driving growth in a specific Multiple Sclerosis patient population

Table of Contents

1. Report Introduction

2. Multiple Sclerosis Epidemiology Overview at a Glance

  • 2.1. Patient Share Distribution of Multiple Sclerosis in 2016
  • 2.2. Patient Share Distribution of Multiple Sclerosis in 2028

3. Disease Background and Overview: Multiple Sclerosis

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Multiple Sclerosis in 7MM
  • 4.3. Total Prevalent/ Incident Patient Population of Multiple Sclerosis in 7MM - By Countries

5. Epidemiology of Multiple Sclerosis by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.1.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.1.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.1.5. Diagnosed Cases of the Multiple Sclerosis
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.4.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.4.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.4.5. Diagnosed Cases of the Multiple Sclerosis
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.5.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.5.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.5.5. Diagnosed Cases of the Multiple Sclerosis
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.6.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.6.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.6.5. Diagnosed Cases of the Multiple Sclerosis
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.7.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.7.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.7.5. Diagnosed Cases of the Multiple Sclerosis
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.8.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.8.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.8.5. Diagnosed Cases of the Multiple Sclerosis
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.9.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.9.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.9.5. Diagnosed Cases of the Multiple Sclerosis

6. Unmet Needs of the Multiple Sclerosis

7. Appendix

8. Report Methodology

  • 8.1. Sources

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

Indication Specific